Literature DB >> 25473380

The First Amendment Right to Speak About the Human Genome.

Barbara J Evans1.   

Abstract

This article explores whether laws that restrict the communication of genetic test results may, under certain circumstances, violate the First Amendment to the U.S. Constitution. The focus is whether investigators have a right to return results from non-CLIA-certified laboratories in situations where a research participant requests the results and the investigator is willing to share them but is concerned that doing so may violate regulations under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA"). This article takes no position on whether investigators can be compelled to return results when they do not wish to do so. It examines only whether investigators may, not whether they must, return results to a willing research participant. The article: (1) surveys state and federal laws that block communication of genetic test results to research participants; (2) examines the historical use of speech restrictions as a tool for protecting human research subjects; (3) traces how First Amendment doctrine has evolved since the 1970s when foundations of modern research bioethics were laid; (4) inquires whether recent bioethical and policy debate has accorded due weight to the First Amendment. The article applies two common methods of legal analysis, textual and constitutional analysis. It concludes that the CLIA regulations, when properly construed, do not treat the return of results as an event that triggers CLIA's certification requirements. Moreover, there is a potential First Amendment problem in construing CLIA's research exception in a way that bans the return of results from non-CLIA-certified laboratories.

Entities:  

Year:  2014        PMID: 25473380      PMCID: PMC4249692     

Source DB:  PubMed          Journal:  Univ Pa J Const Law        ISSN: 1521-2823


  21 in total

1.  Courts are arriving at a consensus on Food and Drug Administration speech regulation.

Authors:  Richard A Samp
Journal:  Food Drug Law J       Date:  2003       Impact factor: 0.619

2.  From sequencing to annotating: extending the metaphor of the book of life from genetics to genomics.

Authors:  Iina Hellsten
Journal:  New Genet Soc       Date:  2005-12

3.  Can speech by FDA-regulated firms ever be noncommercial?

Authors:  Nathan Cortez
Journal:  Am J Law Med       Date:  2011

4.  Off-label drug use and promotion: balancing public health goals and commercial speech.

Authors:  Aaron S Kesselheim
Journal:  Am J Law Med       Date:  2011

5.  Reporting genetic results in research studies: summary and recommendations of an NHLBI working group.

Authors:  Ebony B Bookman; Aleisha A Langehorne; John H Eckfeldt; Kathleen C Glass; Gail P Jarvik; Michael Klag; Greg Koski; Arno Motulsky; Benjamin Wilfond; Teri A Manolio; Richard R Fabsitz; Russell V Luepker
Journal:  Am J Med Genet A       Date:  2006-05-15       Impact factor: 2.802

Review 6.  Managing incidental findings in human subjects research: analysis and recommendations.

Authors:  Susan M Wolf; Frances P Lawrenz; Charles A Nelson; Jeffrey P Kahn; Mildred K Cho; Ellen Wright Clayton; Joel G Fletcher; Michael K Georgieff; Dale Hammerschmidt; Kathy Hudson; Judy Illes; Vivek Kapur; Moira A Keane; Barbara A Koenig; Bonnie S Leroy; Elizabeth G McFarland; Jordan Paradise; Lisa S Parker; Sharon F Terry; Brian Van Ness; Benjamin S Wilfond
Journal:  J Law Med Ethics       Date:  2008       Impact factor: 1.718

7.  The Role of Law in the Debate over Return of Research Results and Incidental Findings: The Challenge of Developing Law for Translational Science.

Authors:  Susan M Wolf
Journal:  Minn J Law Sci Technol       Date:  2012

8.  The Informed Cohort Oversight Board: From Values to Architecture.

Authors:  Ingrid A Holm; Patrick L Taylor
Journal:  Minn J Law Sci Technol       Date:  2012

9.  The legal risks of returning results of genomics research.

Authors:  Ellen Wright Clayton; Amy L McGuire
Journal:  Genet Med       Date:  2012-02-09       Impact factor: 8.822

10.  Minimizing liability risks under the ACMG recommendations for reporting incidental findings in clinical exome and genome sequencing.

Authors:  Barbara J Evans
Journal:  Genet Med       Date:  2013-09-12       Impact factor: 8.822

View more
  9 in total

1.  Automatic Placement of Genomic Research Results in Medical Records: Do Researchers Have a Duty? Should Participants Have a Choice?

Authors:  Anya E R Prince; John M Conley; Arlene M Davis; Gabriel Lázaro-Muñoz; R Jean Cadigan
Journal:  J Law Med Ethics       Date:  2015       Impact factor: 1.718

2.  Barbarians at the Gate: Consumer-Driven Health Data Commons and the Transformation of Citizen Science.

Authors:  Barbara J Evans
Journal:  Am J Law Med       Date:  2016-11

3.  "Bridge to the Literature"? Third-Party Genetic Interpretation Tools and the Views of Tool Developers.

Authors:  Sarah C Nelson; Stephanie M Fullerton
Journal:  J Genet Couns       Date:  2018-02-07       Impact factor: 2.537

4.  Key Expert Stakeholder Perceptions of the Law of Genomics: Identified Problems and Potential Solutions.

Authors:  Fook Yee Cheung; Lauren Clatch; Susan M Wolf; Ellen Wright Clayton; Frances Lawrenz
Journal:  J Law Med Ethics       Date:  2020-03       Impact factor: 1.718

5.  Engaging Hmong adults in genomic and pharmacogenomic research: Toward reducing health disparities in genomic knowledge using a community-based participatory research approach.

Authors:  Kathleen A Culhane-Pera; Robert J Straka; MaiKia Moua; Youssef Roman; Pachia Vue; Kang Xiaaj; May Xia Lo; Mai Lor
Journal:  J Community Genet       Date:  2017-01-10

6.  Return of genomic results to research participants: the floor, the ceiling, and the choices in between.

Authors:  Gail P Jarvik; Laura M Amendola; Jonathan S Berg; Kyle Brothers; Ellen W Clayton; Wendy Chung; Barbara J Evans; James P Evans; Stephanie M Fullerton; Carlos J Gallego; Nanibaa' A Garrison; Stacy W Gray; Ingrid A Holm; Iftikhar J Kullo; Lisa Soleymani Lehmann; Cathy McCarty; Cynthia A Prows; Heidi L Rehm; Richard R Sharp; Joseph Salama; Saskia Sanderson; Sara L Van Driest; Marc S Williams; Susan M Wolf; Wendy A Wolf; Wylie Burke
Journal:  Am J Hum Genet       Date:  2014-05-08       Impact factor: 11.025

7.  Power to the People: Data Citizens in the Age of Precision Medicine.

Authors:  Barbara J Evans
Journal:  Vanderbilt J Entertain Technol Law       Date:  2017

8.  The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.

Authors:  Barbara J Evans
Journal:  Food Drug Law J       Date:  2015       Impact factor: 0.619

9.  Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry.

Authors:  Mercy Y Laurino; Anjali R Truitt; Lederle Tenney; Douglass Fisher; Noralane M Lindor; David Veenstra; Gail P Jarvik; Polly A Newcomb; Stephanie M Fullerton
Journal:  Mol Genet Genomic Med       Date:  2017-08-23       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.